NASDAQ: TRXBTrex Bio Inc Stock
$13.60-0.43 (-3.06%)
Updated Oct 13, 2026
TRXB Price
$13.60
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$13.47
52 Week High
$15.50
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.07
Operating Cash Flow
N/A
Beta
-67.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TRXB Overview
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TRXB's potential to beat the market
- TRXB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TRXB
RankedUnranked of 458
RankedUnranked of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.12 | A | |
| $7.48 | A | |
| $109.62 | A |
Be the first to know about important TRXB news, forecast changes, insider trades & much more!
TRXB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRXB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRXB's short-term assets ($93.26M) exceed its short-term liabilities ($7.66M)
Short-term Liabilities Financials
TRXB's short-term assets ($93.26M) exceed its long-term liabilities ($1.33M)
Long-term Liabilities Financials
TRXB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more TRXB due diligence checks available for Premium users.
Valuation
TRXB's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$96.6M
Liabilities
$9.0M
Debt to equity
-0.07
TRXB's short-term assets ($93.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRXB's short-term assets ($93.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRXB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRXB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
TRXB vs Biotech Stocks
Trex Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.